179 related articles for article (PubMed ID: 30306370)
1. ASO Author Reflections: Cytoreduction for Extrahepatic Metastatic Neuroendocrine Tumors.
Chan DL; Hallet J
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):866-867. PubMed ID: 30306370
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Long-Term Outcomes after Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases.
Gudmundsdottir H; Halfdanarson TR; Nagorney DM; Cleary SP
Ann Surg Oncol; 2023 Aug; 30(8):4852-4853. PubMed ID: 36940040
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: The Role of Primary Tumor Resection in Metastatic Midgut Neuroendocrine Tumor.
Polcz M; Bailey C
Ann Surg Oncol; 2020 Aug; 27(8):2804-2805. PubMed ID: 32447654
[No Abstract] [Full Text] [Related]
4. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
[TBL] [Abstract][Full Text] [Related]
5. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.
Morgan RE; Pommier SJ; Pommier RF
Surgery; 2018 Jan; 163(1):218-225. PubMed ID: 29103583
[TBL] [Abstract][Full Text] [Related]
6. Aggressive resection of neuroendocrine tumor (NET) liver metastases: NET neutral or gain?
Cisco R; Lin D; Kebebew E
Surgery; 2019 Jan; 165(1):176-177. PubMed ID: 30266442
[No Abstract] [Full Text] [Related]
7. First experience of durable cytoreduction in chronic lymphoid leukemia with
Savovic T; Prior JO; Nicod-Lalonde M; Bressoud A; Roux S; Schaefer N; Meyer M
Med Oncol; 2019 Mar; 36(5):41. PubMed ID: 30919094
[TBL] [Abstract][Full Text] [Related]
8. Discussion.
Surgery; 2019 Jan; 165(1):175. PubMed ID: 30527001
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: Safety of Abdominal Surgical Cytoreduction Combined with Locoregional Chemohyperthermia.
Piso P
Ann Surg Oncol; 2019 Jan; 26(1):155. PubMed ID: 30478632
[No Abstract] [Full Text] [Related]
10. Partial hepatic resections for metastatic neuroendocrine tumors: perioperative outcomes.
Kinney MAO; Nagorney DM; Clark DF; O'Brien TD; Turner JD; Marienau ME; Schroeder DR; Martin DP
J Clin Anesth; 2018 Dec; 51():93-96. PubMed ID: 30098573
[TBL] [Abstract][Full Text] [Related]
11. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
[TBL] [Abstract][Full Text] [Related]
12. ASO Author Reflections: Readmission-Free Survival: A Novel Clinical and Quality Outcome Measure for Metastatic Spine Tumor Surgical Patients.
Kumar N
Ann Surg Oncol; 2021 May; 28(5):2483-2484. PubMed ID: 33259042
[No Abstract] [Full Text] [Related]
13. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.
Bertani E; Falconi M; Grana C; Botteri E; Chiappa A; Misitano P; Spada F; Ravizza D; Bazolli B; Fazio N
Int J Surg; 2015 Aug; 20():58-64. PubMed ID: 26074290
[TBL] [Abstract][Full Text] [Related]
14. ASO Author Reflections: Heterogeneity of Duodenal Neuroendocrine Tumors.
Massironi S; Rossi RE
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):858-859. PubMed ID: 30145647
[No Abstract] [Full Text] [Related]
15. ASO Author Reflections: Abandoning the Drains by Eliminating the Radical Procedures Necessitating the Drains.
Weber WP
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):671-672. PubMed ID: 30374930
[No Abstract] [Full Text] [Related]
16. ASO Author Reflections: High-Quality Perioperative and Surgical Therapy: The Impact of Tumor Response in Survival.
Coimbra FJF; da Costa WL
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):729-730. PubMed ID: 32661857
[No Abstract] [Full Text] [Related]
17. ASO Author Reflections: Contact Between T and N Classifications in Pancreatic Neuroendocrine Neoplasms.
Xu JZ; Wang WQ; Liu L; Yu XJ
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):814-815. PubMed ID: 30302639
[No Abstract] [Full Text] [Related]
18. ASO Author Reflections: Perioperative Targeting of the Pre-metastatic Niche Reduces Metastatic Risk After Resection of Solid Tumors.
Tang F; Tu C; Wei X
Ann Surg Oncol; 2021 Jul; 28(7):4049-4050. PubMed ID: 33403523
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: Systemic Inflammatory Markers in Pancreatic Neuroendocrine Tumors.
Gaitanidis A; Patel D; Kebebew E
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):874-875. PubMed ID: 30353397
[No Abstract] [Full Text] [Related]
20. ASO Author Reflections: Surgery and Bevacizumab in Ovarian Cancer.
Petrillo M; Scambia G; Fagotti A
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):886-887. PubMed ID: 30414040
[No Abstract] [Full Text] [Related]
[Next] [New Search]
